10-K: TC BioPharm Faces Going Concern Doubts Despite Progress in Cell Therapy Development

TC BioPharm's annual report reveals ongoing losses and doubts about its ability to continue as a going concern, despite advancements in its gamma delta T-cell therapy programs.

Summary

• TC BioPharm, a clinical-stage biopharmaceutical company, is focused on developing novel immunotherapies using its proprietary gamma delta T-cell platform.
• The company's lead product, OmnImmune, is undergoing Phase 2b-into-pivotal (Phase 3) clinical studies for the treatment of acute myeloid leukemia (AML).
• TC BioPharm is also developing genetically modified CAR-T products for solid tumors, aiming to improve cell navigation and persistence.
• The company has a GMP-compliant manufacturing facility in Scotland, which allows for in-house production of its cell therapies.
• TC BioPharm has incurred net losses of 5.9 million in 2023 and 1.3 million in 2022, with an accumulated deficit of 38.8 million as of December 31, 2023.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• TC BioPharm's cash on hand was 1.7 million as of March 22, 2024, which is insufficient to fund operations through April 1, 2025.
• The company is seeking additional funding through various sources, including equity financings and collaborations.
• TC BioPharm has received FDA orphan drug status for the treatment of AML.
• The company has a strong intellectual property portfolio with 16 granted patents and 11 patent applications.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the company's technology and clinical progress, the financial situation and going concern doubts significantly weigh down the overall sentiment. The company's future is highly dependent on its ability to raise additional capital.

Positives

• The company has a proprietary allogeneic gamma delta T-cell platform.
• TC BioPharm has a fully integrated GMP manufacturing facility.
• The company has a strong intellectual property portfolio.
• TC BioPharm has received FDA orphan drug designation for AML.

Negatives

• TC BioPharm has incurred significant net losses since inception.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company's cash on hand is insufficient to fund operations through April 1, 2025.
• The company has limited operating history and no approved products.
• The company is heavily dependent on the success of its lead product candidate, OmnImmune.

Risks

• The company may not be able to obtain additional financing on acceptable terms or at all.
• Clinical trials may be delayed or unsuccessful.
• Regulatory approvals may be delayed or not obtained.
• The company faces substantial competition from other biotechnology and pharmaceutical companies.
• The company may be subject to product liability claims.
• The company may not be able to protect its intellectual property.
• The company may experience difficulties in managing its growth.
• The company may fail to maintain proper and effective internal controls.
• The company's ADSs could be delisted from trading on Nasdaq.
• The company is subject to a wide array of regulations in the UK, EU and US.

Future Outlook

The company plans to continue to develop its pipeline of GD-T cell therapies, including advancing OmnImmune into Phase 3 clinical trials and progressing its CAR-T programs for solid tumors. The company also plans to expand its manufacturing capabilities and explore opportunities in infectious diseases. The company expects to require additional capital to fund these activities.

Management Comments

• The company believes that its existing cell and gene manufacturing facility in the UK has the capacity to support its committed clinical development plans.
• The company plans to continue to build upon this to support expansion of its product pipelines to new assets and to grow its clinical team.
• The company also will work closely with vendors to embrace emerging technologies in our manufacturing operations that are appropriate and optimized for our products to continually improve the quality and efficiency of our manufacturing systems.
• The company believes that maintaining in-house control of these activities is critical to effective and efficient progression and will continue to seek to build integrated business functions where possible.

Industry Context

The document highlights the competitive landscape in the cell therapy space, with companies like AdicetBio, Allogene, Autolus, and In8Bio also developing cell-based products. TC BioPharm differentiates itself through its proprietary co-stimulatory CAR-T technology, in-house manufacturing, and allogeneic cell banks.

Comparison to Industry Standards

• TC BioPharm's approach to CAR-T therapy using gamma delta T-cells is distinct from the more common alpha-beta T-cell CAR-T therapies used by companies like Novartis and Gilead.
• Unlike autologous CAR-T therapies, TC BioPharm is focused on allogeneic therapies, which aim to reduce manufacturing costs and complexity.
• The company's in-house manufacturing capabilities are a competitive advantage compared to companies that outsource GMP formulation.
• TC BioPharm's co-stimulatory CAR-T approach aims to address the safety concerns associated with conventional CAR-T therapies, such as cytokine release syndrome and off-target toxicities.
• The company's focus on solid tumors with CAR-T therapies is a challenging area where conventional CAR-T therapies have had limited success.

Legal Proceedings

• The company is contesting a claim in the English courts related to a convertible loan note, where the holder is demanding payment of approximately $860,000.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be affected by potential restructuring or layoffs if the company's financial situation does not improve.
• Patients may benefit from the development of new therapies, but the company's financial instability could impact the timeline for product availability.
• Suppliers and creditors may face uncertainty regarding payment due to the company's financial challenges.

Next Steps

• The company plans to continue to advance its clinical programs, including the Phase 3 trial for OmnImmune in AML.
• The company will continue to develop its CAR-T platform for solid tumors.
• The company will seek additional funding to support its operations and development activities.
• The company will continue to explore opportunities in infectious diseases.

Key Dates

Keywords

Gamma Delta T-cells, Immunotherapy, CAR-T, Acute Myeloid Leukemia, AML, Biopharmaceutical, Clinical Trials, Manufacturing, Orphan Drug Designation, Intellectual Property